

Ulcerative Colitis

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

Trial Status
Not Yet Recruiting

Trial Runs In
0 Countries

Trial Identifier
NCT06693908 GA45735

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT06693908 GA45735
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
